| 前收盘价格 | 1.45 |
| 收盘价格 | 1.43 |
| 成交量 | 45,801 |
| 平均成交量 (3个月) | 155,379 |
| 市值 | 161,148,112 |
| 预期市盈率 (P/E Forward) | 116.28 |
| 价格/销量 (P/S) | 3.90 |
| 股市价格/股市净资产 (P/B) | 2.72 |
| 52周波幅 | |
| 利润日期 | 25 Feb 2025 |
| 营业毛利率 | -47.87% |
| 营业利益率 (TTM) | -49.16% |
| 稀释每股收益 (EPS TTM) | -0.130 |
| 季度收入增长率 (YOY) | 43.00% |
| 总债务/股东权益 (D/E MRQ) | 19.39% |
| 流动比率 (MRQ) | 3.99 |
| 营业现金流 (OCF TTM) | -12.57 M |
| 杠杆自由现金流 (LFCF TTM) | -10.21 M |
| 资产报酬率 (ROA TTM) | -16.80% |
| 股东权益报酬率 (ROE TTM) | -35.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Distribution (AU) | 混合的 | 混合的 |
| Medical Distribution (全球的) | 看跌 | 看跌 | |
| 股票 | CYCLOPHARM FPO [CYC] | - | - |
AIStockmoo 评分
0.4
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.38 |
|
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment. |
|
| 部门 | Healthcare |
| 行业 | Medical Distribution |
| 投资方式 | Small Core |
| 内部持股比例 | 48.68% |
| 机构持股比例 | 21.62% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合